Skip to content

4516.T

Nippon Shinyaku Co.,Ltd.

プライム · 医薬品 · 医薬品 · JP

JPY 3,499.00
+0.06%
Ask drillr

Year over year

Reported trailing growth

Revenue
+5.9%
EBITDA
EBIT
-1.6%
EPS
-1.8%
Free cash flow
+40.8%
Operating cash flow
+22.6%

Forward estimates

Based on analyst estimates

Revenue
+2.4%
EBITDA
EPS
-11.9%

Three-year CAGR

Revenue
+5.2%
EBITDA
+3.4%
EBIT
+2.5%
Net income
+9.2%
EPS
+9.2%
Free cash flow
+21.7%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026